Welcome to our dedicated page for INVO BioScience news (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO BioScience stock.
INVO Bioscience, Inc. (Nasdaq: INVO) is a healthcare services company dedicated to expanding access to advanced reproductive technology. Specializing in fertility treatment, INVO focuses on making fertility care more accessible and inclusive. The company operates through dedicated fertility clinics called INVO Centers, and also acquires profitable in vitro fertilization (IVF) clinics in the United States. Their proprietary technology, the INVOcell® device, allows fertilization and early embryo development to occur within a woman's body, a groundbreaking method known as Intravaginal Culture (IVC).
INVO Bioscience's recent strategic initiatives have included the acquisition of US-based IVF clinics and the opening of three INVO Centers in North America. The company's commercial strategy is built around selling products directly to physicians, and via distributors to IVF centers and medical practices.
On October 23, 2023, INVO announced a definitive merger agreement with NAYA Biosciences Inc. The merger, an all-stock transaction, aims to form a combined entity named NAYA Biosciences, which will operate under a NASDAQ listing. The merged company will focus on fertility, oncology, and regenerative medicine, leveraging NAYA's capabilities in cell and gene therapy, and artificial intelligence.
The merger is expected to provide INVO with new capital to expand its fertility clinic network across the United States and advance NAYA's oncology therapeutics. This agreement is a major step forward, with NAYA's shareholders set to own approximately 88% of the combined company and INVO shareholders 12%, pending shareholder approval and other conditions.
Financially, INVO Bioscience has shown a strong performance with significant revenue growth. For the three months ended September 30, 2023, the company reported a revenue increase of 314% compared to the same period in 2022. The company's ongoing strategic focus aims at achieving profitability by 2024, fueled by growth from its INVO Centers and efficient management of operating expenses.
INVO Bioscience is committed to making advanced fertility treatments more affordable and accessible worldwide, offering a natural and less invasive alternative to traditional IVF methods with the INVOcell® device.
INVO Bioscience (NASDAQ: INVO) reported its financial results for Q4 and FY 2022, indicating a revenue of
INVO Bioscience (NASDAQ: INVO) is set to announce its financial results for Q4 and fiscal year 2022, ending December 31, 2022, after market close on
INVO Bioscience, Inc. (NASDAQ: INVO) reported preliminary financial results for Q4 and the full year of 2022. Q4 revenue is expected to increase by 15% to 19%, projecting between $270,000 and $280,000, compared to $235,321 in Q3. Full-year revenue for 2022 is anticipated to rise 38% to 40%, estimating $815,000 to $825,000, up from $588,687 in 2021. However, gross revenue for 2022 is expected to decline by roughly 80% due to the termination of a licensing agreement. INVO also reported ongoing clinic revenue growth and the execution of a significant clinic acquisition, aimed at enhancing their business strategy.
FAQ
What is the current stock price of INVO BioScience (INVO)?
What is the market cap of INVO BioScience (INVO)?
What is the primary focus of INVO Bioscience?
What is the INVOcell® device?
What recent strategic initiative did INVO Bioscience undertake?
How many INVO Centers are currently operational in North America?
What are the expected benefits of the merger with NAYA Biosciences?
What financial performance did INVO Bioscience report for Q3 2023?
What is the anticipated timeline for INVO Bioscience to achieve profitability?
Who will lead the combined company after the merger with NAYA Biosciences?
What are the main areas of focus for the combined NAYA Biosciences?
Where can shareholders find more information about the proposed merger?
